Continue reading this on our app for a better experience

Open in App
Home Capital Broker's Calls

Monetisation of TalkMed’s stem cell treatment for cancer will have to wait

PC Lee
PC Lee • 2 min read
Monetisation of TalkMed’s stem cell treatment for cancer will have to wait
SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.